JP2022547952A - Ｂｒｄ９二機能性分解誘導薬及びその使用方法 - Google Patents

Ｂｒｄ９二機能性分解誘導薬及びその使用方法 Download PDF

Info

Publication number
JP2022547952A
JP2022547952A JP2022515701A JP2022515701A JP2022547952A JP 2022547952 A JP2022547952 A JP 2022547952A JP 2022515701 A JP2022515701 A JP 2022515701A JP 2022515701 A JP2022515701 A JP 2022515701A JP 2022547952 A JP2022547952 A JP 2022547952A
Authority
JP
Japan
Prior art keywords
group
alkyl
formula
alkylene
heteroalkylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022515701A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022547952A5 (enExample
Inventor
ローバー，ジュリエン
センジック，マーティン
チェン，シン
グード，マリー－リン
ハリントン，エドマンド，マーティン
ホリングワース，グレゴリー，ジョン
ブルペッティ，アンナ
ゾラー，トーマス
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72915891&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2022547952(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2022547952A publication Critical patent/JP2022547952A/ja
Publication of JP2022547952A5 publication Critical patent/JP2022547952A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2022515701A 2019-09-16 2020-09-14 Ｂｒｄ９二機能性分解誘導薬及びその使用方法 Pending JP2022547952A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962900869P 2019-09-16 2019-09-16
US201962900865P 2019-09-16 2019-09-16
US201962900863P 2019-09-16 2019-09-16
US201962900860P 2019-09-16 2019-09-16
US62/900,863 2019-09-16
US62/900,860 2019-09-16
US62/900,865 2019-09-16
US62/900,869 2019-09-16
PCT/US2020/050768 WO2021055295A1 (en) 2019-09-16 2020-09-14 Brd9 bifunctional degraders and their methods of use

Publications (2)

Publication Number Publication Date
JP2022547952A true JP2022547952A (ja) 2022-11-16
JP2022547952A5 JP2022547952A5 (enExample) 2023-09-25

Family

ID=72915891

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022515701A Pending JP2022547952A (ja) 2019-09-16 2020-09-14 Ｂｒｄ９二機能性分解誘導薬及びその使用方法

Country Status (21)

Country Link
US (1) US20220315578A1 (enExample)
EP (1) EP4041724A1 (enExample)
JP (1) JP2022547952A (enExample)
KR (1) KR20220063192A (enExample)
CN (1) CN114641473A (enExample)
AU (1) AU2020349451B2 (enExample)
BR (1) BR112022003514A2 (enExample)
CA (1) CA3153529A1 (enExample)
CO (1) CO2022002842A2 (enExample)
CR (1) CR20220105A (enExample)
DO (1) DOP2022000053A (enExample)
EC (1) ECSP22018571A (enExample)
IL (1) IL290677A (enExample)
JO (1) JOP20220069A1 (enExample)
MX (1) MX2022003102A (enExample)
PE (1) PE20221417A1 (enExample)
PH (1) PH12022550611A1 (enExample)
PY (1) PY2054376A (enExample)
TW (1) TW202123942A (enExample)
UY (1) UY38880A (enExample)
WO (1) WO2021055295A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022547716A (ja) * 2019-09-16 2022-11-15 ノバルティス アーゲー 二機能性分解誘導薬及びそれらの使用方法

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3746135A4 (en) 2018-01-30 2022-03-09 Foghorn Therapeutics Inc. METHODS AND COMPOUNDS FOR TREATMENT OF DISEASE
CN111936498B (zh) 2018-03-26 2024-04-16 诺华股份有限公司 N-(3-(7H-吡咯并[2,3-d]嘧啶-4-基)苯基)苯甲酰胺衍生物
US12384776B2 (en) 2019-01-29 2025-08-12 Foghorn Therapeutics Inc. Compounds and uses thereof
EP3917517A4 (en) 2019-01-29 2023-01-25 Foghorn Therapeutics Inc. CONNECTIONS AND USES THEREOF
CN113874016A (zh) 2019-01-29 2021-12-31 福宏治疗公司 化合物及其用途
US20230066136A1 (en) 2019-01-29 2023-03-02 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2021022163A2 (en) 2019-07-31 2021-02-04 Foghorn Therapeutics Inc. Compounds and uses thereof
CR20220160A (es) 2019-09-16 2022-06-16 Takeda Pharmaceuticals Co Derivados de piridazin-3(2h)-ona fusionados con azol
EP4096651A4 (en) * 2020-01-29 2024-01-24 Foghorn Therapeutics Inc. COMPOUNDS AND THEIR USES
US12528825B2 (en) 2020-01-29 2026-01-20 Foghorn Therapeutics Inc. Compounds and uses thereof
TW202146412A (zh) 2020-03-05 2021-12-16 美商Ｃ４醫藥公司 用於標靶降解brd9之化合物
US11787800B2 (en) 2020-07-29 2023-10-17 Foghorn Therapeutics Inc. BRD9 degraders and uses thereof
US11767330B2 (en) 2021-07-06 2023-09-26 Foghorn Therapeutics Inc. Citrate salt, pharmaceutical compositions, and methods of making and using the same
WO2023039208A1 (en) * 2021-09-09 2023-03-16 C4 Therapeutics, Inc. Selected compounds for targeted degradation of brd9
WO2023109892A1 (zh) * 2021-12-15 2023-06-22 海思科医药集团股份有限公司 一种抑制或降解brd9的化合物及其组合物和药学上的应用
WO2023200800A1 (en) * 2022-04-11 2023-10-19 Foghorn Therapeutics Inc. Methods of treating androgen receptor-independent prostate cancer
WO2024163609A1 (en) * 2023-02-01 2024-08-08 Foghorn Therapeutics Inc. Compositions for treating cancer
KR20260029501A (ko) 2023-05-24 2026-03-04 베액티카 테라퓨틱스 아베 Tead에 대한 결합제로서의 방향족 아미드 및 이의 접합체
CN121816348A (zh) 2023-08-11 2026-04-07 深圳众格生物科技有限公司 一种降解irak4的蛋白降解靶向嵌合体化合物及其应用
CN117229202B (zh) * 2023-11-15 2024-01-26 苏州美诺医药科技有限公司 一种brd9靶向降解化合物的中间体的制备方法
WO2025256550A1 (zh) * 2024-06-12 2025-12-18 杭州中美华东制药有限公司 靶向降解剂配体及连接基的制备方法

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017223452A1 (en) * 2016-06-23 2017-12-28 Dana-Farber Cancer Institute, Inc. Degradation of bromodomain-containing protein 9 (brd9) by conjugation of brd9 inhibitors with e3 ligase ligand and methods of use
JP2018502097A (ja) * 2014-12-23 2018-01-25 ダナ ファーバー キャンサー インスティテュート，インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
JP2018507238A (ja) * 2015-03-05 2018-03-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ブロモドメインｂｒｄ９の阻害剤としての新規ピリジノンおよびイソキノリノン
WO2018064589A1 (en) * 2016-09-29 2018-04-05 Dana-Farber Cancer Institute, Inc. Targeted protein degradation using a mutant e3 ubiquitin ligase
WO2018144649A1 (en) * 2017-01-31 2018-08-09 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
WO2019099926A1 (en) * 2017-11-17 2019-05-23 Arvinas, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
WO2019121562A1 (en) * 2017-12-18 2019-06-27 F. Hoffmann-La Roche Ag Bifunctional inhibitors with egfr having a e3 ubiquitin ligase moiety
WO2019140387A1 (en) * 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
JP2022523073A (ja) * 2019-01-29 2022-04-21 フォグホーン セラピューティクス インコーポレイテッド 化合物及びその使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
US9694084B2 (en) * 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
EP3774808A1 (en) * 2018-03-26 2021-02-17 Novartis AG 3-hydroxy-n-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide derivatives
CN111936498B (zh) * 2018-03-26 2024-04-16 诺华股份有限公司 N-(3-(7H-吡咯并[2,3-d]嘧啶-4-基)苯基)苯甲酰胺衍生物
WO2020051235A1 (en) * 2018-09-04 2020-03-12 C4 Therapeutics, Inc. Compounds for the degradation of brd9 or mth1
EP3917517A4 (en) * 2019-01-29 2023-01-25 Foghorn Therapeutics Inc. CONNECTIONS AND USES THEREOF

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018502097A (ja) * 2014-12-23 2018-01-25 ダナ ファーバー キャンサー インスティテュート，インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
JP2018507238A (ja) * 2015-03-05 2018-03-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ブロモドメインｂｒｄ９の阻害剤としての新規ピリジノンおよびイソキノリノン
WO2017223452A1 (en) * 2016-06-23 2017-12-28 Dana-Farber Cancer Institute, Inc. Degradation of bromodomain-containing protein 9 (brd9) by conjugation of brd9 inhibitors with e3 ligase ligand and methods of use
WO2018064589A1 (en) * 2016-09-29 2018-04-05 Dana-Farber Cancer Institute, Inc. Targeted protein degradation using a mutant e3 ubiquitin ligase
WO2018144649A1 (en) * 2017-01-31 2018-08-09 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
WO2019099926A1 (en) * 2017-11-17 2019-05-23 Arvinas, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
WO2019121562A1 (en) * 2017-12-18 2019-06-27 F. Hoffmann-La Roche Ag Bifunctional inhibitors with egfr having a e3 ubiquitin ligase moiety
WO2019140387A1 (en) * 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
JP2022523073A (ja) * 2019-01-29 2022-04-21 フォグホーン セラピューティクス インコーポレイテッド 化合物及びその使用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BIOCHENKO, I. ET AL.: "Chemical Ligand Space of Cereblon", ACS OMEGA, vol. 3, no. 9, JPN6024035615, 2018, pages 11163 - 11171, ISSN: 0005625129 *
LU, JING ET AL.: "Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4", CHEMISTRY & BIOLOGY, vol. 22, no. 6, JPN6024035616, 2015, pages 755 - 763, ISSN: 0005625130 *
REMILLARD, D. ET AL.: "Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands", ANGEWANDTE CHEMIE, INTERNATIONAL EDITION, vol. 56, no. 21, JPN6024035613, 2017, pages 5738 - 5743, ISSN: 0005625127 *
ZOPPI, V. ET AL.: "Iterative Design and Optimization of Initially Inactive Proteolysis Targeting Chimeras (PROTACs) Ide", JOURNAL OF MEDICINAL CHEMISTRY, vol. 62, no. 2, JPN6024035614, 2019, pages 699 - 726, ISSN: 0005625128 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022547716A (ja) * 2019-09-16 2022-11-15 ノバルティス アーゲー 二機能性分解誘導薬及びそれらの使用方法
JP7785663B2 (ja) 2019-09-16 2025-12-15 ノバルティス アーゲー 二機能性分解誘導薬及びそれらの使用方法

Also Published As

Publication number Publication date
AU2020349451B2 (en) 2024-02-01
CN114641473A (zh) 2022-06-17
EP4041724A1 (en) 2022-08-17
KR20220063192A (ko) 2022-05-17
PY2054376A (es) 2021-09-07
PH12022550611A1 (en) 2023-03-13
BR112022003514A2 (pt) 2022-05-17
WO2021055295A1 (en) 2021-03-25
ECSP22018571A (es) 2022-04-29
US20220315578A1 (en) 2022-10-06
JOP20220069A1 (ar) 2023-01-30
AU2020349451A1 (en) 2022-04-21
MX2022003102A (es) 2022-04-06
PE20221417A1 (es) 2022-09-20
IL290677A (en) 2022-04-01
DOP2022000053A (es) 2023-01-31
CR20220105A (es) 2022-06-13
CO2022002842A2 (es) 2022-04-19
UY38880A (es) 2021-04-30
TW202123942A (zh) 2021-07-01
CA3153529A1 (en) 2021-03-25

Similar Documents

Publication Publication Date Title
JP2022547952A (ja) Ｂｒｄ９二機能性分解誘導薬及びその使用方法
JP7811578B2 (ja) 中環状または大環状ベンジル置換複素環誘導体およびオレキシン－２受容体アゴニストとしてのそれらの使用
CN105209448B (zh) 三环化合物及其用途
JP2022547716A (ja) 二機能性分解誘導薬及びそれらの使用方法
TW201524953A (zh) 治療活性化合物及其使用方法（二）
JP2025516367A (ja) Ｐａｒｐ１を選択的に阻害するフルオロキノキサリノン誘導体
CN112020496A (zh) 作为rho激酶抑制剂的苯并吡唑类化合物
CN115698023A (zh) 作为mcl-1抑制剂的大环2-氨基-3-氟-丁-3-烯酰胺
WO2008069242A1 (ja) 新規２環性複素環化合物
CN113698390B (zh) 用作ret激酶抑制剂的化合物及其应用
US20250236629A1 (en) Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and related uses
CN114096546A (zh) 用作mcl-1抑制剂的大环螺环衍生物
JP2019521167A (ja) アミノピリジン誘導体およびそれらの選択的ａｌｋ−２阻害剤としての使用
KR20220113773A (ko) 사이클린 의존성 키나아제 9 억제제로서의 화합물 및 그의 용도
EP3983387B1 (en) Sulfonylurea derivatives and uses thereof
CN111683936B (zh) 多取代苯环化合物、制备方法及其用途
KR20180053357A (ko) 2,3,4,5-테트라히드로피리딘-6-아민 유도체
EP4061819A1 (en) Macrocyclic indole derivatives as mcl-1 inhibitors
WO2023093832A1 (zh) 三并环衍生物及其制备方法和应用
CN114728986A (zh) 作为mcl-1抑制剂的大环磺酰基衍生物
CN107428682A (zh) 酰胺类衍生物、其制备方法及其在医药上的用途
TW201404772A (zh) 噁唑烷酮類衍生物、其製備方法及其在醫藥上的應用
CN116670141A (zh) 作为mcl-1抑制剂的大环支化3-氟-丁-3-烯酰胺
CN116710458A (zh) 作为mcl-1抑制剂的支链大环4-(吡唑-5-基)-吲哚衍生物
KR20260053336A (ko) Erk의 활성 조절을 위한 화합물 및 조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230912

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230912

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240829

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240910

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250624

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251120

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260203